Anthera Pharmaceuticals (ANTH) 10.94 $ANTH
Thrombocytopenia Pipeline Review, H1 2015 - 35 Companies & 41 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqnh8b/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Anthera Pharmaceuticals Inc. - Archemix Corp. - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - Bayer AG - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Cellerant Therapeutics, Inc. - Eisai Co., Ltd. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - InvivoGen Therapeutics - Jiangsu Hengrui Medicine Co., Ltd. - Kaketsuken K.K. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Myelo Therapeutics GmbH - Neumedicines Inc. - Novartis AG - Octapharma AG - Omeros Corporation - Pfizer Inc. - PhytoHealth Corporation - Portola Pharmaceuticals, Inc. - Prophylix Pharma AS - Protalex, Inc. - Rigel Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - STATegics, Inc. - ViroMed Co., Ltd. Drug Profiles - Antibody for Autoimmune Disorders and Inflammation - ARC-15105 - avatrombopag - BAX-930 - BBT-030 - BBT-045 - BI-655064 - BL-8040 - blisibimod - BMS-986004 - caplacizumab - CLT-009 - eltrombopag olamine - fostamatinib disodium - GBR-600 - Gene Therapy for Chemotherapy-Induced Thrombocytopenia - GL-2045 - GSK-2285921 - Hetrombopag Olamine - HL-161 - LUNAR-TPO - lusutrombopag - MK-8723 - Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Myelo-001 - NMIL-121 - Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - OMS-721 - PEG-VM501 - PHN-013 - plasma (human) - PRT-060318 - PRTX-100 - rivaroxaban For more information visit http://www.researchandmarkets.com/research/jq...ocytopenia
IMMU: 2.06 (-0.01), PTLA: 50.27 (-1.03), PFE: 35.82 (-0.29), BMY: 65.06 (+0.22), GSK: 44.17 (+0.72), RIGL: 3.21 (+0.05), MNTA: 23.12 (+1.07), OMER: 15.77 (+0.15), ANTH: 10.94 (+0.23), MRK: 59.10 (+0.40), NVS: 103.25 (-0.32)
Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update on August 10
GlobeNewswire - Thu Jul 30, 4:10PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015.
ANTH: 10.94 (+0.23)
Ascites Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4zf7gm/ascites_global) has announced the addition of the "Ascites Global Clinical Trials Review, H1, 2015" report to their offering. "Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies / Institutions - Sanofi - Otsuka Holdings Co., Ltd. - Simcere Pharmaceutical Group - Shire Plc - Neovii Biotech GmbH - Neopharm Ltd. - Grifols, S.A. - Ferring International Center S.A. . - Anthera Pharmaceuticals Inc. - Govind Ballabh Pant Hospital - Otsuka Beijing Research Institute - The University of Tokyo - Austin Health - Azienda Ospedaliero Universitaria molinette San Giovanni Battista di Torino - Boston Medical Center - Chinese PLA General Hospital - Copenhagen University Hospital Hvidovre - Dong-A University For more information visit http://www.researchandmarkets.com/research/4z...tes_global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ANTH: 10.94 (+0.23), SHPG: 253.75 (+0.15)
Global Glomerulonephritis Clinical Trials Review 2015
M2 - Mon Jul 27, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjc7bk/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Glomerulonephritis Therapeutics Clinical Trials - Regulus Therapeutics Inc. - GlaxoSmithKline plc - Celldex Therapeutics, Inc. - Anthera Pharmaceuticals Inc. - Pharmalink AB - Osprey Pharmaceuticals U.S.A., Inc. - La Jolla Pharmaceutical Company - Daiichi Sankyo Company, Limited - Bristol-Myers Squibb Company - Amgen Inc. - The National Institute of Diabetes and Digestive and Kidney Diseases - Chinese PLA General Hospital - Chinese University of Hong Kong - Columbia University - Hospital Authority - Mayo Clinic For more information visit http://www.researchandmarkets.com/research/hj...onephritis
ANTH: 10.94 (+0.23), CLDX: 23.56 (+0.26), AMGN: 176.44 (+1.64), RGLS: 7.25 (-0.52), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22)
Gilead (GILD) to Report Q2 Earnings: Surprise in the Cards? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 2:30PM CDT
Gilead Sciences Inc. (GILD) is scheduled to report second-quarter 2015 results on Jul 28.
IMDZ: 19.41 (-0.55), GILD: 118.66 (-0.21), MDCO: 31.77 (+0.75), ANTH: 10.94 (+0.23)
Should You Sell Anthera Pharmaceuticals (ANTH) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 7:50AM CDT
Anthera Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat
ANTH: 10.94 (+0.23)
4 Momentum Charts to Watch
at The Street - Thu Jul 23, 3:03PM CDT
A lot of stocks we follow are continuing their upward moves after a brief market swoon.
NUAN: 18.24 (+0.17), ANTH: 10.94 (+0.23), JUNO: 46.67 (+0.17), CHKP: 82.18 (+0.55)
Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 8:04AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) was a big mover last session, as the company saw its shares rise 13% on the day.
ANTH: 10.94 (+0.23), AMAG: 69.36 (+2.26)
An Odd Mix of Action
at The Street - Mon Jul 20, 3:13PM CDT
A few big-cap names drove minor gains in the indices.
AMBA: 115.05 (+0.40), SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), GPRO: 62.67 (+0.59), TSLA: 270.13 (+3.85), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01), AAPL: 115.40 (+0.76)
This Action Is Deceptive
at The Street - Mon Jul 20, 12:18PM CDT
Facebook, Tesla create illusion that the action is better than it really is.
SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), TSLA: 270.13 (+3.85), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01)
Don't Overreact if Charts Start Basing
at The Street - Mon Jul 20, 9:33AM CDT
Current weakness is not necessarily a negative sign.
SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jul 14, 11:05AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are approximately $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
ANTH: 10.94 (+0.23)
A Chinese Financial Implosion Might Spur Opportunities - Here Are 4 Stocks to Watch
ACCESSWIRE - Tue Jul 14, 7:30AM CDT
WINDSOR, ON / ACCESSWIRE / July 14, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on recent developments in the global financial markets.
LIFE: 20.85 (+0.97), ANTH: 10.94 (+0.23), XOMA: 0.90 (+0.12)
Anthera Pharmaceuticals prices public offering at USD7.50 per share
M2 - Fri Jul 10, 3:24AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) said on Thursday that it has priced its public offering of 3,333,334 shares of its common stock.
ANTH: 10.94 (+0.23)
The Reason Behind Anthera Pharmaceuticals' Nasty Tumble
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 09, 2:53PM CDT
What: Shares of Anthera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on treating patients in a wide array of unmet indications, tumbled as much as 10% during Thursday's trading session after announcing a public stock...
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering
at The Street - Thu Jul 09, 10:08AM CDT
Anthera Pharmaceuticals (ANTH) stock is lower after the company priced its public offering of about 3.3 million shares.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Jul 09, 8:00AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be approximately $25 million. The offering is expected to close on or about July 14, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals to issue common stock in public offering
M2 - Thu Jul 09, 3:06AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) stated on Wednesday that it plans to issue and sell shares of its common stock in a public offering.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jul 08, 3:02PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ANTH: 10.94 (+0.23)
Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Jul 06, 2:58PM CDT
Biogen has been underperforming lately, consider these biotech stocks instead.
BIIB: 335.41 (+5.03), CBM: 53.82 (+1.72), ANTH: 10.94 (+0.23), OSIR: 18.83 (-2.02)
Thrombocytopenia Pipeline Review, H1 2015 - 35 Companies & 41 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqnh8b/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Anthera Pharmaceuticals Inc. - Archemix Corp. - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - Bayer AG - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Cellerant Therapeutics, Inc. - Eisai Co., Ltd. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - InvivoGen Therapeutics - Jiangsu Hengrui Medicine Co., Ltd. - Kaketsuken K.K. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Myelo Therapeutics GmbH - Neumedicines Inc. - Novartis AG - Octapharma AG - Omeros Corporation - Pfizer Inc. - PhytoHealth Corporation - Portola Pharmaceuticals, Inc. - Prophylix Pharma AS - Protalex, Inc. - Rigel Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - STATegics, Inc. - ViroMed Co., Ltd. Drug Profiles - Antibody for Autoimmune Disorders and Inflammation - ARC-15105 - avatrombopag - BAX-930 - BBT-030 - BBT-045 - BI-655064 - BL-8040 - blisibimod - BMS-986004 - caplacizumab - CLT-009 - eltrombopag olamine - fostamatinib disodium - GBR-600 - Gene Therapy for Chemotherapy-Induced Thrombocytopenia - GL-2045 - GSK-2285921 - Hetrombopag Olamine - HL-161 - LUNAR-TPO - lusutrombopag - MK-8723 - Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Myelo-001 - NMIL-121 - Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - OMS-721 - PEG-VM501 - PHN-013 - plasma (human) - PRT-060318 - PRTX-100 - rivaroxaban For more information visit http://www.researchandmarkets.com/research/jq...ocytopenia
IMMU: 2.06 (-0.01), PTLA: 50.27 (-1.03), PFE: 35.82 (-0.29), BMY: 65.06 (+0.22), GSK: 44.17 (+0.72), RIGL: 3.21 (+0.05), MNTA: 23.12 (+1.07), OMER: 15.77 (+0.15), ANTH: 10.94 (+0.23), MRK: 59.10 (+0.40), NVS: 103.25 (-0.32)
Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update on August 10
GlobeNewswire - Thu Jul 30, 4:10PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015.
ANTH: 10.94 (+0.23)
Ascites Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4zf7gm/ascites_global) has announced the addition of the "Ascites Global Clinical Trials Review, H1, 2015" report to their offering. "Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies / Institutions - Sanofi - Otsuka Holdings Co., Ltd. - Simcere Pharmaceutical Group - Shire Plc - Neovii Biotech GmbH - Neopharm Ltd. - Grifols, S.A. - Ferring International Center S.A. . - Anthera Pharmaceuticals Inc. - Govind Ballabh Pant Hospital - Otsuka Beijing Research Institute - The University of Tokyo - Austin Health - Azienda Ospedaliero Universitaria molinette San Giovanni Battista di Torino - Boston Medical Center - Chinese PLA General Hospital - Copenhagen University Hospital Hvidovre - Dong-A University For more information visit http://www.researchandmarkets.com/research/4z...tes_global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ANTH: 10.94 (+0.23), SHPG: 253.75 (+0.15)
Global Glomerulonephritis Clinical Trials Review 2015
M2 - Mon Jul 27, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjc7bk/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Glomerulonephritis Therapeutics Clinical Trials - Regulus Therapeutics Inc. - GlaxoSmithKline plc - Celldex Therapeutics, Inc. - Anthera Pharmaceuticals Inc. - Pharmalink AB - Osprey Pharmaceuticals U.S.A., Inc. - La Jolla Pharmaceutical Company - Daiichi Sankyo Company, Limited - Bristol-Myers Squibb Company - Amgen Inc. - The National Institute of Diabetes and Digestive and Kidney Diseases - Chinese PLA General Hospital - Chinese University of Hong Kong - Columbia University - Hospital Authority - Mayo Clinic For more information visit http://www.researchandmarkets.com/research/hj...onephritis
ANTH: 10.94 (+0.23), CLDX: 23.56 (+0.26), AMGN: 176.44 (+1.64), RGLS: 7.25 (-0.52), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22)
Gilead (GILD) to Report Q2 Earnings: Surprise in the Cards? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 2:30PM CDT
Gilead Sciences Inc. (GILD) is scheduled to report second-quarter 2015 results on Jul 28.
IMDZ: 19.41 (-0.55), GILD: 118.66 (-0.21), MDCO: 31.77 (+0.75), ANTH: 10.94 (+0.23)
Should You Sell Anthera Pharmaceuticals (ANTH) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 7:50AM CDT
Anthera Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat
ANTH: 10.94 (+0.23)
4 Momentum Charts to Watch
at The Street - Thu Jul 23, 3:03PM CDT
A lot of stocks we follow are continuing their upward moves after a brief market swoon.
NUAN: 18.24 (+0.17), ANTH: 10.94 (+0.23), JUNO: 46.67 (+0.17), CHKP: 82.18 (+0.55)
Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 8:04AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) was a big mover last session, as the company saw its shares rise 13% on the day.
ANTH: 10.94 (+0.23), AMAG: 69.36 (+2.26)
An Odd Mix of Action
at The Street - Mon Jul 20, 3:13PM CDT
A few big-cap names drove minor gains in the indices.
AMBA: 115.05 (+0.40), SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), GPRO: 62.67 (+0.59), TSLA: 270.13 (+3.85), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01), AAPL: 115.40 (+0.76)
This Action Is Deceptive
at The Street - Mon Jul 20, 12:18PM CDT
Facebook, Tesla create illusion that the action is better than it really is.
SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), TSLA: 270.13 (+3.85), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01)
Don't Overreact if Charts Start Basing
at The Street - Mon Jul 20, 9:33AM CDT
Current weakness is not necessarily a negative sign.
SGYP: 8.51 (-0.17), SEDG: 30.75 (+1.03), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), ANTH: 10.94 (+0.23), FB: 96.44 (+2.38), GOOGL: 673.29 (+12.01)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jul 14, 11:05AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are approximately $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
ANTH: 10.94 (+0.23)
A Chinese Financial Implosion Might Spur Opportunities - Here Are 4 Stocks to Watch
ACCESSWIRE - Tue Jul 14, 7:30AM CDT
WINDSOR, ON / ACCESSWIRE / July 14, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on recent developments in the global financial markets.
LIFE: 20.85 (+0.97), ANTH: 10.94 (+0.23), XOMA: 0.90 (+0.12)
Anthera Pharmaceuticals prices public offering at USD7.50 per share
M2 - Fri Jul 10, 3:24AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) said on Thursday that it has priced its public offering of 3,333,334 shares of its common stock.
ANTH: 10.94 (+0.23)
The Reason Behind Anthera Pharmaceuticals' Nasty Tumble
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 09, 2:53PM CDT
What: Shares of Anthera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on treating patients in a wide array of unmet indications, tumbled as much as 10% during Thursday's trading session after announcing a public stock...
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offering
at The Street - Thu Jul 09, 10:08AM CDT
Anthera Pharmaceuticals (ANTH) stock is lower after the company priced its public offering of about 3.3 million shares.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Jul 09, 8:00AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be approximately $25 million. The offering is expected to close on or about July 14, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals to issue common stock in public offering
M2 - Thu Jul 09, 3:06AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) stated on Wednesday that it plans to issue and sell shares of its common stock in a public offering.
ANTH: 10.94 (+0.23)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jul 08, 3:02PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ANTH: 10.94 (+0.23)
Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Jul 06, 2:58PM CDT
Biogen has been underperforming lately, consider these biotech stocks instead.
BIIB: 335.41 (+5.03), CBM: 53.82 (+1.72), ANTH: 10.94 (+0.23), OSIR: 18.83 (-2.02)
